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Purpose Obesity can make bone marrow biopsy using manual landmarks as guid-
ance technically challenging. This retrospective review was performed to assess the 
safety and technical success of performing bone marrow biopsies with computed 
tomography (CT)–guidance in obese patients.
Materials and Methods This single-institution, retrospective study included 1,016 
CT-guided bone marrow biopsies performed between 2009 and 2016. Thirty-four per-
cent (n = 348) were performed in patients with a body mass index (BMI) of 30 kg/m2 
or greater, and 7% (n = 75) were performed in patients with a BMI greater than 40 kg/
m2. Demographic information, BMI, and complications were reviewed. The primary 
endpoint was technical success and procedurally related hemorrhagic complication. 
The electronic medical record was reviewed to identify procedural related hemorrhag-
ic complications, Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 
or above. The complication rates in obese patients were compared with patients with 
a BMI less than 30 kg/m2.
Results Biopsy was successfully performed in all patients. No biopsies resulted in 
a CTCAE Grade 3 or above complication. There was no difference in complication 
rate (0%) based on BMI. For patients with a BMI < 30 kg/m2, BMI ≥ 30 kg/m2, and 
BMI > 40 kg/m2, complications rates were 0% (95% confidence interval [CI]: 0–0.4%), 
0% (95% CI: 0–0.9%), and 0% (95% CI: 0–4%), respectively.
Conclusions CT-guided bone marrow biopsy in obese patients can be performed 
with a high rate of technical success and is safe. If patient body habitus limits the 
ability to palpate physical landmarks needed to perform bone marrow biopsy without 
image guidance, CT-guided bone marrow biopsy should be considered.
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Introduction
Bone marrow biopsy and aspiration is a commonly per-
formed procedure, used to aid in the diagnosis, monitoring, 
and staging of multiple diseases, primarily hematologic or 
metastatic in nature. The retrieved specimens provide vital 
information regarding the patient’s disease, through the use 
of immunohistochemical stains, cytogenetic analysis, flow 
cytometry, and molecular assays.1,2
Overall, bone marrow biopsy is a safe procedure, with 
a complication rate of less than 0.1%.3-5 The most common 
complication reported is hemorrhage.3,4,6 Obese patients tend 
to have higher levels of coagulation factors and lower levels 
of tissue plasminogen activator (t-PA) activity,7 and some 
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studies have shown increased bleeding in patients undergo-
ing percutaneous coronary intervention with a lower body 
mass index (BMI).8 This data suggests that obesity could 
potentially protect against bleeding; however, obesity is a 
risk factor for hemorrhage after bone marrow biopsy.3,5,6 
Excess adipose tissue can make bedside bone marrow biop-
sies technically challenging due to the loss of physical land-
marks used to guide biopsy.9,10
Performing a bedside bone marrow biopsy without pal-
pable physical landmarks risks neurovascular injury if the 
 needle is advanced into an adjacent tissue compartment 
other than the iliac bone. If the gluteal compartment is 
entered, there is risk of gluteal artery hemorrhage, pseu-
doaneurysm, or gluteal compartment syndrome.5,11 If the 
needle is advanced too deeply and penetrates the inner iliac 
cortex, it can result in iliac and/or pelvic vessel injury and 
lead to retroperitoneal hemorrhage.5,11
Use of computed tomography (CT)–guidance has been 
proven to be safe and efficacious for liver and renal biop-
sies in obese patients, with the added benefit of more rapid 
identification of complications.11-13 This retrospective review 
was performed to test the hypothesis that performing bone 
marrow biopsies with CT guidance in obese patients is tech-
nically feasible and safe.
Materials and Methods
This institutional review board–approved study was designed 
as a retrospective cohort study with the primary endpoint 
being the occurrence of Common Terminology Criteria 
for Adverse Events (CTCAE) Grade 3 or above hemorrhagic 
 complication.14 There was a waiver granted for informed 
consent, compliant with the Health Insurance Portability and 
Accountability Act. The authors have no conflicts of interest 
to report.
Patient Selection
A database of bone marrow biopsies performed within our 
institution between May 1, 2009, and May 1, 2016, was retro-
spectively collected with patients identified using Montage 
Search and Analytics software (Montage Healthcare Solu-
tions). All patients who underwent CT-guided bone marrow 
biopsies were included. Patients who underwent bone mar-
row biopsy without CT-guidance were excluded along with all 
biopsies outside of the approved study time frame. Patients 
who did not have weight or height documented within one 
month of the biopsy were also excluded. A total of 1,023 bone 
marrow biopsies were performed using CT guidance during 
the study period; 7 were excluded because weight or height 
was not documented. The patients in this study were previ-
ously studied to assess the impact of platelet count on risk of 
hemorrhagic complication.15 Although the biopsies were per-
formed in a hospital setting, the study population included 
both inpatients and outpatients.
Of the final population of 1,016 biopsies, mean age was 
57 years (range 15–93 years), 492 patients were female 
(48%), and 524 patients were male (52%). Thirty-four percent 
(n = 348) of bone marrow biopsies were performed on inpa-
tients with a BMI of 30 kg/m2 or greater.
Biopsy Procedure
Procedural consents were obtained prior to the start of each 
procedure. After positioning the patient in the prone posi-
tion, sedation was administered by either the interventional 
radiologist or separate anesthesia staff. Although sedation 
information was not assessed in these patients, at the per-
forming institution, sedation is typically performed with a 
combination of midazolam, fentanyl, and/or propofol for 
these procedures. A limited field of view low-dose CT scan 
of the pelvis was then obtained for procedural planning. For 
local anesthesia, 2% lidocaine was administered along the 
expected needle trajectory, to include the skin and perios-
teum of the posterior superior iliac crest. A Carefusion AVA-
max 11-gauge coaxial biopsy needle system (BD-Carefusion) 
was advanced through the cortical bone where an aspirate 
and core biopsy was obtained (►Fig.  1). The bone marrow 
aspiration was performed by attaching a syringe to the 
11-guage access cannula. Subsequently, a single core biopsy 
with a 14-guage biopsy needle was performed through the 
access cannula. All patients were instructed to lie flat on 
their back for 1 hour after the procedure and vital signs were 
monitored every 15 minutes during recovery. Nursing staff 
was instructed to inform the interventional radiologist if the 
patient experienced increased pain or bleeding at the biopsy 
site. After 1 hour in recovery, inpatients were transported to 
their hospital room and outpatients were allowed to go home 
(with a driver).
Fig. 1 Axial computed tomography (CT) image in bone window 
demonstrates a biopsy needle extending into the posterior right iliac 
bone, through the use of a lateral approach. Note the prominent sub-
cutaneous tissue, which could potentially limit use of guidance using 
anatomic landmarks.
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Assessment of Complications
Each patient’s medical record was reviewed, including the 
48 hours following each biopsy to identify CTCAE Grade 3 or 
above complications. A Grade 3 arterial injury complication 
is defined as any injury that results in severe symptoms and 
requires repair or intervention. The electronic medical record 
was reviewed for all patients, with attention for any postpro-
cedural imaging demonstrating a biopsy site hematoma, any 
hemoglobin drop greater than 2 g/dL following the proce-
dure, or any evidence of sustained hemodynamic instability 
requiring initiation of vasopressors. Subjective biopsy site 
pain/discomfort without corresponding vital sign instability 
or biopsy site bleeding/hematoma was not considered a sig-
nificant complication.
Statistical Analysis
The hemorrhagic complication rates of the patients were 
calculated for patients with normal BMI, BMI of 30 kg/m2 
or greater, and BMI greater than 40 kg/m2. The complication 
rates for obese patients (BMI ≥ 30 kg/m2 and BMI > 40 kg/m2) 
were compared with patients with BMI less than 30 kg/m2. 
Two-tailed 95% confidence intervals based on Poisson dis-
tribution for complication rate in obese patients were also 
calculated. Continuous data are presented as mean and 
standard deviation and compared using the unpaired t-test. 
 Categorical data are presented as percentages and counts and 
compared using the chi-square test. SPSS v.22.0.0 (SPSS Inc.) 
was used for statistical analysis.
Results
Of the 1,016 patients in the study population, 348 were had a 
BMI ≥ 30 kg/m2 and 75 had a BMI > 40 kg/m2. The highest BMI 
included in our study population was 66.7 kg/m2. Thirty-seven 
percent of the female population was obese, with 8% having 
a BMI > 40 kg/m2. Thirty-one percent of the male population 
was classified as obese, with 6% having a BMI > 40 kg/m2. This 
was not significantly different between groups (p = 0.12). 
Demographic information is presented in ►Table 1.
Technical success was achieved in all patients. Out of 
1,016 biopsies, 0 resulted in a complication. No interventions 
or transfusions were needed for procedure-related bleeding. 
There were no instances of clinically symptomatic bleeding 
and no imaging was performed for suspicion of bleeding. 
There was no difference in rate of hemorrhagic complica-
tions (0%) based on BMI (p = 1.0). For patients with BMI less 
than 30 kg/m2, the rate for hemorrhagic complications was 
0% (95% confidence interval [CI]: 0–0.4%). For patients with 
a BMI of 30 kg/m2 or greater, the rate for hemorrhagic com-
plications was 0% (95% CI: 0–0.9%). For patients with a BMI 
greater than 40 kg/m2, the rate for hemorrhagic complica-
tions was 0% (95% CI: 0–4%).
Discussion
Bone marrow biopsies are indicated for the diagnostic 
work-up and monitoring of several disease pathologies, 
including malignancy, hematologic abnormalities, and infec-
tion. Most frequently the bone marrow aspiration and core 
biopsy are performed on the posterior superior iliac crest.16 
This is in part due to the accessibility and ease of identifica-
tion of the anatomic landmarks, lack of large overlying ves-
sels or nerves, as well as the characteristically delayed loss of 
cellularity of the axial skeleton. However, in obese patients, 
identification of the anatomic landmarks by physical exam 
can be unreliable, and in this setting, imaging guidance via 
the use of CT is helpful.17 CT-guided bone marrow biopsy 
was technically successful in all of the obese patients, but, 
to the authors knowledge, there is no reported incidence of 
the technical success of blinded bone marrow biopsies in this 
patient population for comparison.
Although bone marrow aspiration and core biopsy is a 
low-risk procedure with rare complications, it is not with-
out risk.3,5 One study of blind bone marrow aspiration for 
reconstructive orthopedic surgery reported a major com-
plication rate of 0.6% and a minor complication rate of 2%.18 
Major complications included hematoma requiring transfu-
sion and gait disturbance for 2 months.18 This study required 
large bone marrow aspiration volumes, so the orthopedic 
surgeons made multiple passes into the bone through the 
same skin incision which may have resulted in a higher 
incidence of complication compared with diagnostic (low- 
volume) bone marrow aspiration.18 Another study reported 
hemorrhage in only 0.07% of patients; however, it was “life- 
threatening or contributed to death” in 3 of the 10 patients 
who suffered this complication.4 Reported risk factors for 
hemorrhagic complication after bone marrow biopsy include 
a diagnosis of a myeloproliferative disorder, aspirin therapy, 
warfarin  therapy, disseminated intravascular coagulation 
(DIC), thrombocytopenia ranging from 25,000–68,000/µL, 
and obesity.3,5 To the authors’ knowledge, no prior study 
evaluates complication rate of bone marrow biopsy or aspi-
ration in the obese population. While some make the argu-
ment that a highly experienced operator can successfully 
perform bone marrow biopsies without anatomic land-
marks, others advocate for the use of CT guidance to safely 
Table 1  Patient demographic information
Men (n = 524) Women (n = 492) p-value
n % n %
BMI <30 kg/m2 360 69% 308 63% 0.12
BMI: 30–40 kg/m2 130 25% 143 29%
BMI >40 kg/m2 34 6% 41 8%
Age (y) 58 15.1 57.4 15.2 0.55
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perform the procedure. Devaliaf and Tudor were some of the 
first to advocate the use of CT guidance for bone marrow 
biopsy of hematologic disorders, rather than just for osseous 
lesions.9 In response, Ghosh stated that CT-guided biopsy is 
rarely needed, unless unguided biopsy fails and an anterior 
approach is to be attempted.9,19
Worldwide obesity has tripled since 1975,20 and will likely 
lead to increased obesity-related morbidity in medicine. While 
bone marrow biopsy complications may not be directly asso-
ciated with obesity, the inciting factor is often an inability to 
determine landmarks and/or needle position.21-26 Performing 
bone marrow biopsy under CT guidance eliminates the need 
for bony landmarks and should be considered as a safe alter-
native in these patients.
This study is limited by the retrospective nature of the study, 
which lends itself to selection bias. Patients in this cohort are, 
by nature, more likely to be sicker than those in whom the 
referring physician felt comfortable performing the biopsy at 
bedside or in clinic. However, this would further support the 
safety of CT-guided bone marrow biopsies in the obese popu-
lation. Furthermore, this study was not able to assess if the risk 
hemorrhagic complication in obese patients is reduced by using 
CT guidance because it did not include obese patients who 
underwent blind bone marrow biopsy. In addition, restricting 
the postprocedure observation period to 48 hours could have 
resulted in potentially missing a delayed complication.
This retrospective study demonstrated that CT-guided 
bone marrow biopsy in obese patients is performed with 
high probability of technical success and is safe. In obese 
patients who lack the physical landmarks used to guide bed-
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